Antimicrobial
Protease inhibitors
Block viral polyprotein cleavage
PROH-tee-ays in-HIB-ih-terz
High-yield clue
Without protease cleavage the virion assembles but stays immature and non-infectious.
Overview
An antiviral class (the '-navir' drugs) whose mechanism concept is blocking a viral protease so precursor polyproteins are never cut into functional proteins, teaching the maturation step of viral assembly.
Classification
- Antiviral
- Enzyme inhibitor
- '-navir' suffix vocabulary
- HIV and HCV protease targets
Lab & identification clues
- Viral protease cleaves polyprotein into structural/enzymatic proteins vocabulary
- Blocking maturation yields non-infectious particles concept
- Ritonavir as a pharmacokinetic booster vocabulary
Associations
- HIV combination-therapy study framing
- Hepatitis C direct-acting antiviral vocabulary
- Viral assembly and maturation concept
Commonly confused with
- Reverse transcriptase inhibitors
- Beta-lactamase inhibitors (bacterial, unrelated)
Your notes
Original mechanism summary for microbiology study. Sources checked: CDC antimicrobial-resistance guidance, NCBI Bookshelf Medical Microbiology, and standard coursework frameworks; reviewed 2026-06. Covers class, mechanism, and resistance vocabulary only; no prescribing, dosing, or patient-specific treatment guidance.